Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.09 USD
-0.11 (-2.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 21 - 40 ( 406 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Business Update Provided; Anaphylm Development on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm - Competitor neffy Hits Snag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Development Plan Unaffected by neffy CRL; Libervant 2-5yo NDA Accepted
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Anaphylm Pivotal Protocol Submitted to FDA; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q2:23 Financials; Pivotal PK Trial Protocol for Anaphylm Submitted to the FDA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Additional Anaphylm Pharmacokinetic Data Released; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Crossover Study Validates Dosing Instructions; Pivotal PK Study in Q4:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
NDA Submitted for Libervant in 2-5yo; FDA Acceptance of NDA Likely in Q3:23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Neffy Developments May Bode Well for Anaphylm, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Positive Anaphylm- Clinical Data; Pivotal Trial Starting Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Additional Studies Support Anaphylm''s Fast Time to Rescue; Pivotal Study in Q4
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Upcoming Epi Alternative AdCom & Read Through to AQST-109; Q1:23 Financials
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Eyes Remain on AQST-109; Libervant License Expansion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
U/g to OP Due to Extended Cash Runway; AQST-109/Anaphylaxis Updates; Q4/FY22
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
KOL Call Invite: Shaking up the Epi Market with No-Needle Alternatives
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A